FDA Adds Boxed Warning to Type 2 Diabetes Medication Canagliflozin
Based on new data from two large clinical trials, the U.S. Food and Drug Administration (FDA) is adding a boxed warning to the type 2 diabetes medication canagliflozin (available in products - Invokana, Invokamet, Invokamet XR) due to an increased risk of leg and foot amputations.
Patients taking canagliflozin should be counseled to notify their health care professionals right away if they develop new pain or tenderness, sores or ulcers, or infections in their legs or feet.